Acceleron Pharma Inc - Company Profile
Powered by
All the data and insights you need on Acceleron Pharma Inc in one report.
- Save hours of research time and resources with
our up-to-date Acceleron Pharma Inc Strategy Report
- Understand Acceleron Pharma Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Acceleron Pharma Inc (Acceleron) is a clinical stage biopharmaceutical company that discovers, develops and commercializes drugs to treat serious and rare diseases. Reblozyl is the company’s only commercial product used for the treatment of transfusion-dependent anemia patients with beta thalassemia and myelodysplastic syndromes (MDS). The company’s lead therapeutic candidate, luspatercept-aamt is in clinical trials for the treatment of anemia and associated complications in myelodysplastic syndromes, and myelofibrosis. Its other pipeline products are being evaluated for the treatment of lung disease. The company has operations in the US, Bermuda and Switzerland. Acceleron Pharma is headquartered in Cambridge, Massachusetts, the US.
Acceleron Pharma Inc premium industry data and analytics
Products and Services
Products |
---|
Commercial: |
Reblozyl (luspatercept-aamt)- for anemia with beta-thalassemia and myelodysplastic syndromes patients. |
Pipeline Product: |
XYZ |
XYZ |
XYZ |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer